Aurinia Pharmaceuticals Inc Stock Forecast

NASDAQ:AUPH Open Broker Account

$4.88 (-1.31%)

Volume: 869.603k

Closed: Nov 25, 2022

Hollow Logo Score: -3.449

Aurinia Pharmaceuticals Inc Stock Forecast

$4.88 (-1.31%)

Volume: 869.603k

Closed: Nov 25, 2022

Score Hollow Logo -3.449

AUPH Price Targets and Analyst Ratings NASDAQ:AUPH

Last Reaction
Be the first to comment on AUPH

AUPH Forecast. What You Should Know.

AUPH Historical Ratings and Targets

FAQ

What are analyst ratings?
Analyst ratings are recommendations made by various stock analysts. Public companies are rated by analysts who monitor their industries. These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts. Read More...

What to keep in mind using analyst ratings?
The best way to use analyst ratings is to supplement your investment research. Please do not rely on them blindly; instead, use them as one tool in your decision-making process. Also, be sure to pay attention to the date of the rating. Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today. Read More...

What is a price target in trading?
A price target is a stock market term used by investors and analysts to indicate the level at which they believe a stock will trade. The price target is based on several factors, including a company's earnings, revenue, and valuation. Determining a price target can be tricky, as it is an estimate and not always accurate. However, it can guide investors looking to buy or sell a stock. Read More...

Unlock All Premium Features! Go Premium! Only $9.95/Month

Unlock the Top 5 candidates in every list
Unlock full Ultimate List Builder
Golden Star lists & Auto Portfolios
Possible Runners & Moving Average lists
Ad-free browsing
Save data in PDF

Hot Stocks To Watch:

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.... AUPH Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT